NCT04565249View on ClinicalTrials.gov

Evaluation of the Safety, Tolerability, and Pharmacokinetics of PLN-74809 in Participants With Acute Respiratory Distress Syndrome (ARDS) Associated With at Least Severe COVID-19

PHASE2TerminatedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

October 22, 2020

Primary Completion Date

June 1, 2021

Study Completion Date

August 2, 2021

Conditions
Acute Respiratory Distress SyndromeSARS-CoV-2
Interventions
DRUG

PLN-74809

PLN-74809

DRUG

Placebo

Placebo

Trial Locations (6)

30912

Augusta University Medical Center, Augusta

32803

Advent Health, Orlando

80206

National Jewish Health, Denver

85008

Valleywise Health Medical Center, Phoenix

90048

Cedars-Sinai Medical Center, Los Angeles

07960

Atlantic Health System, Summit

Sponsors
All Listed Sponsors
lead

Pliant Therapeutics, Inc.

INDUSTRY

NCT04565249 - Evaluation of the Safety, Tolerability, and Pharmacokinetics of PLN-74809 in Participants With Acute Respiratory Distress Syndrome (ARDS) Associated With at Least Severe COVID-19 | Biotech Hunter | Biotech Hunter